The treatment of lung cancer with personalized medicine has come a long way in recent decades, but still more achievements remain to be seen, said Bruce Johnson, MD, FASCO, immediate past president of the American Society of Clinical Oncology, during his keynote speech opening the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology in Kissimmee, Florida.
"By being a part of this membership, you get access to education, information, resources, [and] materials that are hopefully going to be helpful in the care of cancer patients," said Rick McDonough, MD, president of the Florida Society of Clinical Oncology (FLASCO).
The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
The guidances released by the FDA to expand inclusion criteria for cancer clinical trials is a step in the right direction, said Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
Xarzio currently has the majority of the market share for filgrastim products, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
Technology allows for additional avenues to engage with patients and make us more available to them, explained Brian MacDonald, PharmD, manager, Specialty Clinical Programs, Magellan Rx Management.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses results from Oncology Care Model (OCM) performance period 3 (PP3) and challenges his practice still experiences with the model.
Alexandra Quinn, chief executive officer, Health Leads, discusses the growing role of community health workers in cancer care and why it's important to make the work they do more sustainable.
Oncology needs to learn to use technology not just for keeping medical records, but also for caring for patients, explained Erich Mounce, chief operating officer, OneOncology.
Jeffrey A. Scott, MD, chief medical officer, Integra Connect, discusses how pharma can help community oncologists understand the value of novel and expensive therapies.
Results from performance period 3 (PP3) were somewhat concerning because the amount of practices that achieved a shared savings stayed stable from PP2, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, is harmful to both sides of the doctor-patient relationship, according to Lee B. Schwartzberg, MD, medical director of the West Cancer and Research Institute, who spoke at the 2019 Community Oncology Conference, held in Orlando, Florida.
Healthcare experts may agree the shift from volume to value is well under way, but the definition of value has many answers, according to pharmaceutical company representatives discussing the issue at the 2019 Community Oncology Conference in Orlando, Florida.
C.K. Wang, MD, senior medical director, COTA, explains how COTA's real-world data platform can benefit payers.
As the technology improves, we’re going to see liquid biopsies used in multiple different cancers, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, discusses what's needed from a policy perspective to ensure access to next-generation sequencing (NGS) tests.
Patients won't participate in a clinical trial if it's too much of a burden, so we have to bring the trials to where the patients live, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
At the Community Oncology Alliance's 2019 Community Oncology Conference in Orlando, Florida, a panel discussed strategies for practices to collaborate and survive the recent wave of consolidation. Targeting employers is one solution.
The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model.
There's still a big disparity in reimbursement between hospitals and community-based practices, but is looking into ways to address this, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
Leveraging technology to perform real-time prescription benefit checks could give patients and providers personalized cost knowledge when a drug is being prescribed, but standardization of the process is needed for wider uptake, according to a session at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting.
A trio of posters presented at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting show that high healthcare utilization leads to substantial costs among individuals living with HIV, but prompt initiation of antiretroviral therapy (ART) regimens after diagnosis can help contain costs in both Medicaid-covered and commercially insured patients.
Michael Steinman, MD, professor of medicine, University of California, San Diego, discusses effective strategies for improving medication management for patients and how these strategies can improve outcomes, such as medication adherence.
A study found that out of hundreds of specialty drugs, only 16% were covered in the same way by 17 commercial payers in the United States, meaning that 84% of those specialty drugs had differing coverage, explained James D. Chambers, PhD, MPharm, MSc, associate professor, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.
Panelists discuss what PCSK9 inhibitors are, the evidence to support them, and challenges with operationalizing them in practice.
Gene therapy provides an opportunity for every patient to become not a patient, to become an individual, and you can’t put a cost on that, explained Sophie Schmitz, BA, MA, managing partner, Partners4Access.
The Institute for Clinical and Economic Review will work with drug manufacturers, patients, and clinical experts to get supplemental information of newly approved drugs, explained Steven Pearson, MD, MSc, president, ICER.
Several efforts are underway nearly a year after the Trump administration released its blueprint to lower drug prices in May 2018, but tracking their outcomes depends on what metric is used to define drug prices, according to a session at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting, held March 25-28 in San Diego, California.
Utilization management tools and formulary designs are components of a multifaceted strategy to curb opioid overdose death rates, but they must be applied in a flexible manner, according to speakers at the Academy of Managed Care annual meeting.
Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors, discusses changes to Medicare Part D expected to come in 2020 and their implications.
